SinoMab BioScience Limited — Board/Management Information 2020

Nov 30, 2020

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [29 x 43] intentionally omitted <==

==> picture [29 x 43] intentionally omitted <==

SinoMab BioScience Limited 中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 3681)

RE-DESIGNATION OF DIRECTOR

The board (the “ Board ”) of directors (the “ Directors ”) of SinoMab BioScience Limited (中國抗 體製藥有限公司) (the “ Company ”) hereby announces that due to work rearrangement, Mr. Jing QIANG (強靜) (“ Mr. Qiang ”) has resigned as the president of the Company with effect from 30 November 2020 and has been re-designated from an executive Director to a non-executive Director with effect from the same date.

Mr. Qiang, aged 38, was appointed as a Director and the president of the Company from March 2018 until November 2020. Mr. Qiang has over nine years of experience in the field of medicine and healthcare related research and investment. Mr. Qiang has served as the chairman of Suzhou Sinovent Pharmaceutical Technology Co., Ltd. (蘇州信諾維醫藥科技有限公司). Prior to that, Mr. Qiang worked at China International Capital Corporation Limited (stock code: 3908), a company listed on The Stock Exchange of Hong Kong Limited (the “ Stock Exchange* ”) from July 2010 to March 2018, where he held the position of managing director when he left. During his term with China International Capital Corporation Limited, Mr. Qiang won Asiamoney’s best research coverage in healthcare in 2014 to 2017 and was ranked top three in healthcare by the 2015-2017 China Research Team of Institutional Investor.

Mr. Qiang obtained his bachelor’s degree in pharmacy from Shanghai Jiao Tong University, China (上海交通大學) in July 2005 and his master’s degree in finance from Fudan University, China (復旦大學) in June 2010. Mr. Qiang completed the High Impact Cancer Research (HI-CR) Program of Harvard Medical School in the United States in 2019. Mr. Qiang was qualified as a Chartered Financial Analyst by the CFA Institute in September 2011 and as a Financial Risk Manager by the Global Association of Risk Professionals in April 2009.

Mr. Qiang has entered into an appointment letter with the Company in respect of his re-designation as a non-executive Director for a term of three years from 30 November 2020, during which he shall be subject to retirement and re-election in accordance with the articles of association of the Company. He will be entitled to a director fee of HK$2,000,000 and incentive at the Company’s discretion, as recommended by the remuneration committee of the Company and approved by the Board based on his qualifications, experience, duties and level of responsibilities in the Company.

1

Mr. Qiang is the spouse of Ms. Wenyi LIU. As at the date of this announcement, Mr. Qiang is interested in 34,831,640 shares of the Company, representing 3.46% of the issued shares of the Company, held by his wholly owned subsidiary. For the purpose of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), Mr. Qiang is also deemed to be interested in 212,889,400 shares of the Company, representing 21.16% of the issued shares of the Company through the interests of his spouse.

Save as disclosed above, as at the date of this announcement, Mr. Qiang (i) is not interested in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) is independent from and has no relationship with any Director, senior management, substantial shareholder or controlling shareholder of the Company; (iii) has not held any other major appointments or qualifications or positions with the Company or other members of the Group; and (iv) has not held any directorship in any other listed public corporations in the past three years. Save as disclosed above, there is no information which is discloseable nor is Mr. Qiang involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on the Stock Exchange and there are no other matters concerning Mr. Qiang that need to be brought to the attention of the shareholders of the Company.

By Order of the Board SinoMab BioScience Limited Dr. Shui On LEUNG Executive Director, Chairman and Chief Executive Director

Hong Kong, 30 November 2020

As at the date of this announcement, the executive Director is Dr. Shui On LEUNG, the non-executive Directors are Dr. Haigang CHEN, Mr. Xun DONG, Mr. Senlin LIU, Ms. Wenyi LIU, Mr. Huiyuan MA and Mr. Jing QIANG, and the independent non-executive Directors are Mr. George William Hunter CAUTHERLEY, Mr. Michael James Connolly HOGAN, Mr. Ping Cho Terence HON and Mr. Dylan Carlo TINKER.

• For identification purposes only

2